The effect of sodium-glucose co-transporter-2 inhibitors on markers of subclinical atherosclerosis.

Further research is needed to investigate the underlying mechanisms and the possible beneficial impact of SGLT2i on primary and secondary CVD prevention through attenuation of premature atherosclerosis progression.